Intresseorganisationer
Projektets/aktivitetens namn:
Dissemination of Psoriasis and Beyond resultsTidplan/datum:
Startdatum: 2023-04-14Slutdatum: 2023-12-31
Läkemedelsföretag:
Novartis Sverige AB (ansvarar för innehållet i denna text)Samarbetspartner:
IFPA - International Federation of Psoriasis AssociationsProjektbeskrivning:
Psoriasis and Beyond is a study designed to assess patients understanding of the systemic nature of their psoriatic disease and the humanistic and physical burden of living with the condition. The study was conducted in collaboration with IFPA and 13 of IFPA’s members. The study protocol and questionnaire were developed with a Steering Committee comprising IFPA, patient advocates and clinical advocates. The global study results have been presented at various scientific congresses including at the Fall Clinical Dermatology 2021 and 2022 conferences, EADV and ACR. A manuscript with global results has been accepted in a peer-reviewed journal and publication is expected imminently. In parallel, a manuscript to publish local data from the US and Canada are under preparations. As the study partner, IFPA is a co-author in all publications.Ekonomi – Belopp i SEK:
102 400Ekonomi – Beskrivning:
EURO 9 000 is the final cost. The sponsorship is broken down into the following activities: Communication efforts throughout the year 2023, using data from the scientific study Psoriasis and Beyond, to amplify IFPA’s cause, activities, and projects, and to mobilize IFPA members who participated in the study for being ambassadors and sharing the results.Övrigt:
Kontaktpersoner:
Novartis Sverige AB, Monia Steenackers, +41 793147963, monia.steenackers@novartis.comIFPA - International Federation of Psoriasis Associations, Frida Dunger Johnsson, 0855610914, frida.dunger-johnsson@ifpa-pso.com